Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan-Mar;26(1):102-7.
doi: 10.4103/0970-1591.60452.

Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor

Geoffrey T Gotto  1 , Brett S Carver, Pramod Sogani, Joel Sheinfeld
Affiliations

Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor

Geoffrey T Gotto et al. Indian J Urol. 2010 Jan-Mar.

Abstract

Recognition of the therapeutic role of retroperitoneal lymph node dissection (RPLND) in the setting of testicular germ cell tumors (GCTs) is of utmost importance. Although the histologic findings of RPLND provide diagnostic and prognostic information, the adequacy of initial RPLND is an independent predictor of clinical outcome. Despite the advent of effective cisplatin-based chemotherapy for testicular GCTs, patients who have undergone suboptimal surgery at the time of initial RPLND are compromised. Despite the initial enthusiasm surrounding anatomic mapping studies, the use of modified RPLND templates has the potential to leave a significant number of patients with unresected retroperitoneal disease. Teratomatous elements are particularly common. Patients with retroperitoneal relapse following initial RPLND should be treated with reoperative RPLND and chemotherapy and can expect long term survival rates nearing 70% when treated in tertiary centers by experienced surgeons.

Keywords: Recurrence; relapse; reoperative; retroperitoneal lymph node dissection; testicular cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:None declared.

Figures

Figure 1
Figure 1
Adverse Impact of Redo-RPLND. Disease-specific survival for patients undergoing reoperative retroperitoneal surgery following primary RPLND (A) and PC-RPLND (B).[4]
See this image and copyright information in PMC

References

    1. Sheinfeld J. Treatment of patients with testis cancer: Introduction. Urol Oncol. 2005;23:222.
    1. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: Current concepts and controversies. Semin Urol Oncol. 2002;20:262. - PubMed
    1. Carver BS, Sheinfeld J. Therapeutic efficacy of laparoscopic RPLND: Unproved and untested. Am J Urol Rev. 2004;2:427.
    1. McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: Clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62:732. - PubMed
    1. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170–6. - PubMed